Curran Daniel J. — SEC Form 4 filings
SEC reporting owner CIK 1887599. 7 Form 4 filings on record with FilingPulse; latest filed 2026-07-17.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-06-17 to 2026-07-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. (CPRX) | Director | 2 | — | — | 5 |
| Xilio Therapeutics, Inc. (XLO) | Director | 3 | — | — | 3 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | Director | 2 | — | — | 2 |
Form 4 filings — Curran Daniel J.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-17 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Disposition to issuer (D): 40,000 (derivative) @ $0 · Disposition to issuer (D): 18,115 (derivative) @ $0 · Disposition to issuer (D): 5,468 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Grant/award (A): 16,833 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Grant/award (A): 18,115 (derivative) @ $0 · Grant/award (A): 5,468 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1887599 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →